Scandion Oncology A/S is a listed Danish biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. The company's first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients.
The company also has several preclinical programs to build a broader pipeline of drugs for the treatment of drug resistant cancer diseases.
Company Details
- Founded
- -
- Address
- Fruebjergvej 3, Copenhagen,dk 2100,denmark
- Phone
- +45 38 10 20 17
- in****@****ogy.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- scandiononcology.com
- HQ
- Copenhagen, DK
Scandion Oncology Questions
Scandion Oncology's helpline number is +45 38 10 20 17
Scandion Oncology's website is scandiononcology.com
Scandion Oncology's LinkedIn profile is https://dk.linkedin.com/company/scandion-oncology
Scandion Oncology's industry is
Biotechnology Research
Scandion Oncology's top competitors are
Io Biotech,
Adcendo,
Union Therapeutics A/s,
Saniona,
River Stone Biotech Inc.,
Hervolution Therapeutics,
Var2 Pharmaceuticals,
2curex - Individualizing Cancer Treatment,
Macure Pharma,
Vipergen Aps.
Scandion Oncology's support email address is info@scandiononcology.com
Scandion Oncology's categories are Biotechnology Research
Scandion Oncology's founding year is 2017
